Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025

Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial evaluating CTIM-76 at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting. The meeting took place from May 30 to June 3 this year in Chicago, IL.

The presentation, titled “A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors,” was held on June 2. The Phase 1 trial for CTIM-76 is an open-label, dose escalation and expansion study. Its primary objective is to evaluate the safety, tolerability, and pharmacokinetics of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers.

Secondary objectives include assessing anti-tumor activity based on overall response rate, duration of response, and disease control rate. Context Therapeutics has made significant progress with the trial, having dosed the first patient in January 2025 and currently administering treatment to cohort 3. The company anticipates sharing initial data from this Phase 1 trial in H1 2026.

Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company that develops products for the treatment of solid tumors.

While we acknowledge the potential of CNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.